Zymeworks Inc.
corporate_fare Company Profile
Zymeworks Inc. (NASDAQ:ZYME) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for ZYME at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for ZYME spans 10-Q, 8-K.
Recent high-impact activity:
- $200M Buyback Authorized, Doubling Down After $125M Program Wrapped
- Zymeworks 10-Q Details $173.7M Q3 Profit, $560M Theravance Deal Accounting
- Zymeworks Raises 2026 Revenue Guidance to $337M-$351M Following $250M Jazz Milestone
- Zymeworks Posts $2.28 Per-Share Profit in Third Quarter
- ZW191 Hits 64.5% Response Rate at 6.4 mg/kg With Half the Severe Toxicity
Financial Snapshot
Short Interest & Short Volume
4.25 days to coverFINRA reported short interest of 5,914,601 shares in ZYME as of the October 30, 2026 settlement, a 6.0% increase from the prior period — about 4.3 days to cover at its recent average daily volume. On November 20, 2026, 68.2% of ZYME volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.